We investigated whether serum neutrophil gelatinase-associated lipocalin (NGAL) was an early predictive biomarker of contrast-induced nephropathy (CIN) in patients with chronic kidney disease (n = 100) undergoing coronary catheterization. Serum creatinine (SCr) levels were measured at baseline, 24 hours, and 48 hours post procedure. Serum NGAL was measured preprocedure, 4 hours, and 24 hours post procedure. The frequency of CIN was 11%. In patients with CIN, SCr achieved significance only at 48 hours (P = .006), whereas serum NGAL increased โฅ25% from baseline at 24 hours in 7 of 11 patients with CIN (P = .04) but did not change in the other 4. However, serum NGAL also rose โฅ25% in 12 of 89 non-CIN patients. This subgroup could have had โincipient CIN.โ Serum NGAL delta value at baseline, 24 hours was superior to SCr for early diagnosis of CIN. In conclusion, serum NGAL is an early predictive biomarker for CIN.
NashKHafeezAHouS. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930โ936.
2.
McCulloughPAWolynRRocherLLLevinRNOโNeillWW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368โ375.
3.
RudnickMRGoldfarbSWexlerL. For the iohexol cooperative study: nephrotoxicity of high-osmolality versus low- osmolality contrast media: a randomized trial. Kidney Int. 1995;47(1):254โ261.
4.
GoldenbergIMatetzkyS. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461โ1471.
5.
BriguoriCManganelliFScarpatoP. Acetylcysteine and contrast agent associated nephrotoxicity. J Am Coll Cardiol. 2002;40(2):298โ303.
6.
TepelMAspelinPLameireN. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113(14):1799โ1806.
7.
LetellierGDesjarlaisF.Analytical interference of drug in clinical chemistry: II - interference of three cephalosporins with the determination of serum creatinine concentration by the Jaffe reaction. Clin Biochem. 1985;18(6):352โ356.
8.
WeberJAVan ZantenAP. Interferences in current methods for measurements of creatinine. Clin Chem. 1991;37(5):695โ700.
9.
LingWZhaohuiNBenH. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008;108(3):176โ181.
10.
Bachorzewska-GajewskaHMalyszkoJSitniewskaE. Could neutrophil gelatinase-associated lipocalin and cystatin C predict the development of contrast induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?Kidney Blood Press Res. 2007;30(6):408โ415.
11.
RickliHBenouKAmmannP. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol. 2004;6(2):98โ102.
12.
IshibashiYYamauchiMMushaHMikamiTKawasakiKMiyakeF. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization. Angiology. 2010;61(8):724โ730.
13.
MoriKLeeHTRapoportD. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610โ621.
14.
MishraJMaQKellyC. Kidney NGAL is a novel early marker of acute renal injury following transplantation. Pediatr Nephrol. 2006;21(6):856โ863.
15.
LeveyASGreeneTKusekJWBeckGJ.A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol. 2000;11:A0828.
16.
BernsAS. Nephrotoxicity of contrast media. Kidney Int. 1989;36(4):730โ740.
17.
MehranRAymongEDNikolskyE. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393โ1399.
18.
FuNLiXYangS. Risk Score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention. Angiology. 2013;64(3):188โ194.
19.
Raposeiras-RoubรญnSAguiar-SoutoPBarreiro-PardalCGRACE risk score predicts contrast-induced nephropathy in patients with acute coronary syndrome and normal renal function. Angiology. 2013;64(1):31โ39.
20.
ElbasanZSahinDYGรผrM. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology. 2014;65(1):37โ42.
21.
SianosGMorelMAKappeteinAP. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. Eurointervention. 2005;1(2):219โ227.
22.
KayJChowWHChanTM. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. A randomized controlled trial. JAMA. 2003;289(5):553โ558.
23.
Diaz-SandovalLJKosowskyBDLosordoDW. Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trial). Am J Cardiol. 2002;89(3):356โ358.
24.
ZainuddinS.A Comparison of Different Treatment Measures to Prevent Contrast-Induced Nephropathy in Patients With Underlying Stable Renal Impairment Undergoing Coronary Angiography. [MMED thesis]. Malaysia: Faculty of Medicine, Universiti Kebangsaan Malaysia; 2004. 9HUKM.WJ342.S681c.
25.
O'SullivanSHealyDAMoloneyMCGracePAWalshSR. The Role of N acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology. 2013;64(8):576โ582.
26.
GoldenbergIShechterMMatetzkyS. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004;25(3):212โ218.
27.
SeyonRAJensenLAFergusonIAWilliamsRG. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention. Heart Lung. 2007:36(3):195โ204.
28.
MarenziGAssanelliEMaranaI. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354(26):2773โ2782.
29.
AlonsoALauJJaberBLWeintraubASarnakMJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis. 2004;43(1):1โ9.
30.
BirckRKrzossokSMarkowetzFSchnullePvan der WoudeFJBraunC. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362(9384):598โ603.
31.
LiuRNairDIxJMooreDHBentS.N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med. 2005;20(2):193โ200.
32.
NallamothuBKShojaniaKGSaintS. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med. 2004;117(12):938โ947.
33.
MarenziGLauriGAssanelliE. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(9):1780โ1785.
34.
GleesonTGBulugahapitiyaS. Contrast-induced nephropathy. AJR Am J Roentgenol. 2004;183(6):1673โ1689.
35.
DetrenisSMeschiMMusiniSSavazziG. Lights and shadows on the pathogenesis of contrast induced nephropathy: state of the art. Nephrol Dial Transplant. 2005;20(8):1542โ1550.
36.
ParfreyPSGriffithsSMBarrettBJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med. 1989;320(3):143โ149.
37.
RihalCSTextorSCGrillDE. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259โ2264.
38.
WeisbergLSKurnikPBKurnikBR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45(1):259โ265.
39.
DangasGIakovouINikolskyE. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13โ19.
BarrettBJCarlisleEJ. Meta-analysis of the relative nephrotoxicity of high โ and low osmolitity iodinated contrast media. Radiology.1993;188(1):171โ178.
42.
AspelinPAubryPFranssonSG. Nephrotoxic effects in high-risk patients undergoing angiography. N Eng J Med. 2003;348(6):491โ499.
43.
CroninRE. Renal failure following radiologic procedures. Am J Med Sci. 1989;298(5): 342โ356.
44.
MurphySWBarrettBJParfreyPS. Contrast nephropathy. J Am Soc Nephrol. 2000;11(1):177โ182.
45.
DevarajanP.Emerging biomarkers of acute kidney injury. Contrib Nephrol. 2007;156:203โ212.
46.
BolignanoDLacquanitiACoppolinoG. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):337โ344.
47.
MitsnefesMMKathmanTSMishraJ. Serum neutrophil gelatinase associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol. 2007;22(1):101โ108.
